News

The approval is based on a large clinical database, comprising data from over 1,300 patients with cUTI across phase 3 studies, including several patients with infections due to

It is the first adalimumab biosimilar candidate recommended for EMA approval. It has been recommended to treat certain inflammatory ailments in adults like moderate-to-severe rheumatoid arthritis, severe ankylosing spondylitis

The Company has now dosed their first human subject with KM-819, an orally active small molecule that is a potentially disease-modifying treatment of Parkinson's Disease. The trial is

Charles Rowland, Chief Executive Officer of Aurinia, said: “Selecting a CRO for AURORA is a key milestone for Aurinia following our successful end-of-Phase 2 meeting with the U.S.

The financing was led by the Global Health Sciences Fund of Quark Venture and GF Securities, along with Mesa Verde Venture Partners. Existing Biscayne Pharmaceuticals investors and new

PF-06425090, following the findings from the pre-planned interim analysis, will now progress towards a phase 3 trial, slated to be initiated in the first half of this year.

Actelion discovers, develops and commercializes new drugs for diseases with significant unmet medical need. As part of the deal, Actelion will spin out its drug discovery operations and

The collaboration will combine Lundbeck's expertise in the treatment of psychiatric and neurological disorders with IBM's cognitive and knowledge-based analytics to foster the discovery and development of new

The options range from retaining the business to separation through a capital markets transaction in order to identify how to best maximize value for the company’s shareholders. Alcon